Efficacy and safety of a hair growth promoting product containing topical 1% melatonin for treatment of androgenetic alopecia in women: A randomized double-blind trial
Phase 2
- Conditions
- Female pattern hair loss (Androgenetic alopecia)
- Registration Number
- TCTR20201227001
- Lead Sponsor
- Faculty of Medicine, Thammasat University (Rungsit campus)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
1. Female pattern hair loss (Androgenetic alopecia), Type II - V of Sinclair scale
2. Healthy status
Exclusion Criteria
1. No topical treatment include minoxidil for AGA within 6 months
2. No topical herb solution for hair growth within 6 months
3. No systemic treatment for AGA within 6 months. For example, oral contraceptive drug, finasteride, dutasteride, spironolactone
4. No history of chemotherapy and radiation within 1 year prior to the clinical trials
5. No topical steroid that apply a scalp at least 14 days within 3 months prior to the trials
6. No pregnancy and breastfeeding status
7. No history of hypersensitivity to melatonin and minoxidil
8. No multiple comorbidities
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Target area hair counts 0,2,4,6 months Leviacam (Trichoscopy)
- Secondary Outcome Measures
Name Time Method Comb-and-Count 0,2,4,6 months number,Global assessment by photo 0,2,4,6 months 7 scales